A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 48, 2012, Pages 19685-19690

  Link, Jason M ^a   Ota, Sara ^a   Zhou, Zi Qiang ^a   Daniel, Colin J ^b   Sears, Rosalie C ^b   Hurlin, Peter J ^a,b  

^a SHRINERS HOSPITAL FOR CHILDREN   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antioxidant; Bcl 2; Buthionine sulfoximine; Cancer; Ras

Indexed keywords

REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; FIBROBLAST; GENE DELETION; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MAXS NEXT TANGO GENE; MOUSE; MOUSE STRAIN; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; REPRESSOR GENE; T LYMPHOCYTE; THYMOMA; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; MICE; PROTO-ONCOGENE PROTEINS C-MYC; REACTIVE OXYGEN SPECIES; REPRESSOR PROTEINS; T-LYMPHOCYTES;

EID: 84870359573     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1206406109     Document Type: Article

References (63)

1. Grandori C, Cowley SM, James LP, Eisenman RN (2000) The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16:653-699.
2. Arvanitis C, Felsher DW (2006) Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol 16(4):313-317.
3. Eilers M, Eisenman RN (2008) Myc's broad reach. Genes Dev 22(20):2755-2766.
4. Dang CV, Le A, Gao P (2009) MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 15(21):6479-6483.
5. van Riggelen J, Yetil A, Felsher DW (2010) MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer 10(4):301-309.
6. Savino M, et al. (2011) The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS ONE 6(7):e22284.
7. Soucek L, Evan GI (2010) The ups and downs of Myc biology. Curr Opin Genet Dev 20(1):91-95.
8. Pelengaris S, Khan M, Evan GI (2002) Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109(3):321-334.
9. Nilsson JA, Cleveland JL (2003) Myc pathways provoking cell suicide and cancer. Oncogene 22(56):9007-9021.
10. Murphy DJ, et al. (2008) Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 14(6):447-457.
11. Lowe SW, Cepero E, Evan G (2004) Intrinsic tumour suppression. Nature 432(7015):307-315.
12. Albihn A, Johnsen JI, Henriksson MA (2010) MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 107:163-224.
13. Hurlin PJ, Quéva C, Eisenman RN (1997) Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. Genes Dev 11(1):44-58.
14. Meroni G, et al. (1997) Rox, a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a non-canonical E box and acts as a transcriptional repressor. EMBO J 16(10):2892-2906.
15. Hurlin PJ, et al. (2003) Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis. EMBO J 22(18):4584-4596.
16. Nilsson JA, et al. (2004) Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation. Mol Cell Biol 24(4):1560-1569.
17. Walker W, Zhou Z-Q, Ota S, Wynshaw-Boris A, Hurlin PJ (2005) Mnt-Max to Myc-Max complex switching regulates cell cycle entry. J Cell Biol 169(3):405-413.
18. Dezfouli S, Bakke A, Huang J, Wynshaw-Boris A, Hurlin PJ (2006) Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells. Mol Cell Biol 26(6):2080-2092.
19. Zhang Z, et al. (2009) MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 8(17):2756-2768.
20. Toyo-oka K, et al. (2006) Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression. Cancer Res 66(11):5565-5573, and correction (2006) 66(13):6894.
21. Pierce SB, et al. (2008) Drosophila growth and development in the absence of dMyc and dMnt. Dev Biol 315(2):303-316.
22. Loo LWM, et al. (2005) The transcriptional repressor dMnt is a regulator of growth in Drosophila melanogaster. Mol Cell Biol 25(16):7078-7091.
23. Hooker CW, Hurlin PJ (2006) Of Myc and Mnt. J Cell Sci 119(Pt 2):208-216.
24. Vasilevsky NA, Ruby CE, Hurlin PJ, Weinberg AD (2011) OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival. Eur J Immunol 41(4):1024-1034.
25. Surh CD, Sprent J (1994) T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372(6501):100-103.
26. de Alboran IM, et al. (2001) Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity 14(1):45-55.
27. Dose M, et al. (2006) c-Myc mediates pre-TCR-induced proliferation but not developmental progression. Blood 108(8):2669-2677.
28. Rudolph B, Hueber A-O, Evan GI (2000) Reversible activation of c-Myc in thymocytes enhances positive selection and induces proliferation and apoptosis in vitro. Oncogene 19(15):1891-1900.
29. Douglas NC, Jacobs H, Bothwell AL, Hayday AC (2001) Defining the specific physiological requirements for c-Myc in T cell development. Nat Immunol 2(4):307-315.
30. Stewart M, et al. (1993) Conditional expression and oncogenicity of c-myc linked to a CD2 gene dominant control region. Int J Cancer 53(6):1023-1030.
31. Wang X, et al. (2011) Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res 71(3):925-936.
32. Xue L, et al. (2010) Coupling of the cell cycle and apoptotic machineries in developing T cells. J Biol Chem 285(10):7556-7565.
33. Michalek RD, Rathmell JC (2010) The metabolic life and times of a T-cell. Immunol Rev 236:190-202.
34. Jones RG, Thompson CB (2007) Revving the engine: Signal transduction fuels T cell activation. Immunity 27(2):173-178.
35. Reed JC, Sabath DE, Hoover RG, Prystowsky MB (1985) Recombinant interleukin 2 regulates levels of c-myc mRNA in a cloned murine T lymphocyte.Mol Cell Biol 5(12):3361-3368.
36. Mukherjee S, Ahmed A, Nandi D (2005) CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A. J Leukoc Biol 78(1):144-157.
37. Kelly K, Cochran BH, Stiles CD, Leder P (1983) Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 35(3 Pt 2):603-610.
38. Henriksson M, Bakardjiev A, Klein G, Lüscher B (1993) Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene 8(12):3199-3209.
39. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG (2000) c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 95(6):2104-2110.
40. Chang DW, Claassen GF, Hann SR, Cole MD (2000) The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol Cell Biol 20(12):4309-4319.
41. Hemann MT, et al. (2005) Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436(7052):807-811.
42. Fanidi A, Harrington EA, Evan GI (1992) Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359(6395):554-556.
43. Todaro GJ, Green H (1963) Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol 17:299-313.
44. Hildeman DA, Mitchell T, Kappler J, Marrack P (2003) T cell apoptosis and reactive oxygen species. J Clin Invest 111(5):575-581.
45. Castedo M, et al. (1995) Mitochondrial perturbations define lymphocytes undergoing apoptotic depletion in vivo. Eur J Immunol 25(12):3277-3284.
46. Eylar E, et al. (1993) N-acetylcysteine enhances T cell functions and T cell growth in culture. Int Immunol 5(1):97-101.
47. Angelini G, et al. (2002) Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci USA 99(3):1491-1496.
48. Noelle RJ, Lawrence DA (1980) Modulation of T-cell functions. I. Effect of 2-mercaptoethanol and macrophages on T-cell proliferation. Cell Immunol 50(2):416-431.
49. Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47:89-116.
50. DeNicola GM, et al. (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475(7354):106-109.
51. Fox CJ, Hammerman PS, Thompson CB (2005) Fuel feeds function: Energy metabolism and the T-cell response. Nat Rev Immunol 5(11):844-852.
52. Toyo-oka K, et al. (2004) Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: Relevance to Miller-Dieker syndrome. Hum Mol Genet 13(10):1057-1067.
53. Nilsson JA, Cleveland JL (2004) Mnt: Master regulator of the Max network. Cell Cycle 3(5):588-590.
54. Chen Y, McMillan-Ward E, Kong J, Israels SJ, Gibson SB (2007) Mitochondrial electron-transport-chain inhibitors of complexes I and II induce autophagic cell death mediated by reactive oxygen species. J Cell Sci 120(Pt 23):4155-4166.
55. Li N, et al. (2003) Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 278(10):8516-8525.
56. Chandel NS, et al. (1998) Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 95(20):11715-11720.
57. Liu W, et al. (2012) Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci USA 109(23):8983-8988.
58. Morrish F, Isern N, Sadilek M, Jeffrey M, Hockenbery DM (2009) c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry. Oncogene 28(27):2485-2491.
59. Wise DR, et al. (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105(48):18782-18787.
60. Vafa O, et al. (2002) c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability. Mol Cell 9(5):1031-1044.
61. Pani G, Galeotti T, Chiarugi P (2010) Metastasis: Cancer cell's escape from oxidative stress. Cancer Metastasis Rev 29(2):351-378.
62. Gao P, et al. (2007) HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12(3):230-238.
63. Zindy F, et al. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12(15):2424-2433.